使用CTLA-4疗法洗牌：重排的TCRB基因深度测序证明癌症患者的T细胞受体库重塑。
Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patients.
作者信息
Cha Edward, Fong Lawrence
机构信息
University of California, San Francisco, San Francisco, CA.
出版信息
Oncoimmunology. 2018 Mar 13;7(4):e956016. doi: 10.4161/21624011.2014.956016. eCollection 2018.
Abstract
CTLA-4 inhibition produces durable T cell-driven antitumor responses, but understanding which patients achieve a long-term benefit remains unclear. Deep sequencing of rearranged T cell receptor β (TCRβ) genes can monitor the effects of CTLA-4 inhibition and potentially identify patients with long-term survival.
摘要
细胞毒性T淋巴细胞相关抗原4（CTLA-4）抑制可产生持久的T细胞驱动的抗肿瘤反应，但哪些患者能获得长期益处仍不清楚。重排的T细胞受体β（TCRβ）基因的深度测序可监测CTLA-4抑制的效果，并有可能识别出长期存活的患者。
相似文献
1
Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patients.使用CTLA-4疗法洗牌：重排的TCRB基因深度测序证明癌症患者的T细胞受体库重塑。
Oncoimmunology. 2018 Mar 13;7(4):e956016. doi: 10.4161/21624011.2014.956016. eCollection 2018.
2
TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer.免疫检查点抑制治疗癌症患者的 TCR 汇聚。
Front Immunol. 2020 Jan 9;10:2985. doi: 10.3389/fimmu.2019.02985. eCollection 2019.
3
Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.放疗和 CTLA-4 阻断塑造肿瘤浸润 T 细胞的 TCR 库。
Cancer Immunol Res. 2018 Feb;6(2):139-150. doi: 10.1158/2326-6066.CIR-17-0134. Epub 2017 Nov 27.
4
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers.抗 CTLA-4 免疫疗法不会耗尽人类癌症中的 FOXP3+调节性 T 细胞（Tregs）。
Clin Cancer Res. 2019 Feb 15;25(4):1233-1238. doi: 10.1158/1078-0432.CCR-18-0762. Epub 2018 Jul 27.
5
Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.治疗性伊匹单抗和曲美木单抗抗体具有显著相似的CTLA-4结合特性。
Oncotarget. 2017 May 19;8(40):67129-67139. doi: 10.18632/oncotarget.18004. eCollection 2017 Sep 15.
6
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.CTLA-4 和 PD-1/PD-L1 阻断：黑色素瘤患者具有持久临床获益的新免疫治疗方式。
Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143.
7
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.癌症患者中CTLA-4阻断引发的免疫毒性与T细胞受体库的早期多样化有关。
Cancer Res. 2017 Mar 15;77(6):1322-1330. doi: 10.1158/0008-5472.CAN-16-2324. Epub 2016 Dec 28.
8
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.深度测序 T 细胞受体 DNA 作为免疫治疗后乳腺癌中克隆扩增 TIL 的生物标志物。
Cancer Immunol Res. 2016 Oct;4(10):835-844. doi: 10.1158/2326-6066.CIR-16-0013. Epub 2016 Sep 1.
9
Therapeutic use of anti-CTLA-4 antibodies.抗CTLA-4抗体的治疗用途。
Int Immunol. 2015 Jan;27(1):3-10. doi: 10.1093/intimm/dxu076. Epub 2014 Jul 18.
10
CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.转移性癌症患者使用单克隆抗体进行CTLA-4阻断：手术相关问题
Ann Surg Oncol. 2008 Nov;15(11):3014-21. doi: 10.1245/s10434-008-0104-y. Epub 2008 Aug 21.
引用本文的文献
1
NHS-IL12, a Tumor-Targeting Immunocytokine.NHS-IL12，一种肿瘤靶向免疫细胞因子。
Immunotargets Ther. 2021 May 27;10:155-169. doi: 10.2147/ITT.S306150. eCollection 2021.
2
T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma.在接受免疫治疗前后，T 细胞受体库的特征与间皮瘤的临床反应相关。
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000251.
3
First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors.针对转移性实体瘤患者的肿瘤靶向细胞因子（NHS-IL12）的首次人体 I 期临床试验。
Clin Cancer Res. 2019 Jan 1;25(1):99-109. doi: 10.1158/1078-0432.CCR-18-1512. Epub 2018 Aug 21.
本文引用的文献
1
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.高效鉴定与持久肿瘤消退相关的T细胞所识别的突变癌症抗原。
Clin Cancer Res. 2014 Jul 1;20(13):3401-10. doi: 10.1158/1078-0432.CCR-14-0433.
2
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.抗 CTLA-4 治疗后肿瘤患者 T 细胞克隆型稳定性改善生存。
Sci Transl Med. 2014 May 28;6(238):238ra70. doi: 10.1126/scitranslmed.3008211.
3
Combining next-generation sequencing and immune assays: a novel method for identification of antigen-specific T cells.结合下一代测序和免疫检测：一种鉴定抗原特异性 T 细胞的新方法。
PLoS One. 2013 Sep 19;8(9):e74231. doi: 10.1371/journal.pone.0074231. eCollection 2013.
4
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.肿瘤外显子分析揭示了在对伊匹单抗有反应的黑色素瘤中存在新抗原特异性T细胞反应性。
J Clin Oncol. 2013 Nov 10;31(32):e439-42. doi: 10.1200/JCO.2012.47.7521. Epub 2013 Sep 16.
5
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.依匹单抗的研发：一种用于治疗晚期黑色素瘤的新型免疫治疗方法。
Ann N Y Acad Sci. 2013 Jul;1291(1):1-13. doi: 10.1111/nyas.12180. Epub 2013 Jun 17.
6
Unmasking the immune recognition of prostate cancer with CTLA4 blockade.用 CTLA4 阻断法揭开前列腺癌的免疫识别。
Nat Rev Cancer. 2012 Mar 1;12(4):289-97. doi: 10.1038/nrc3223.
7
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.同情使用依匹单抗治疗晚期黑色素瘤患者的单机构经验：第 2 剂后淋巴细胞计数与生存相关。
Cancer. 2010 Apr 1;116(7):1767-75. doi: 10.1002/cncr.24951.
8
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.CTLA4阻断可增加转移性黑色素瘤患者的Th17细胞。
J Transl Med. 2009 May 20;7:35. doi: 10.1186/1479-5876-7-35.
9
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.通过CTLA4阻断和GM-CSF联合免疫疗法增强前列腺癌的内源性抗肿瘤免疫力。
Cancer Res. 2009 Jan 15;69(2):609-15. doi: 10.1158/0008-5472.CAN-08-3529.
10
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.细胞毒性T淋巴细胞相关抗原4阻断单克隆抗体曲美木单抗对黑色素瘤患者外周血免疫效应的详细分析。
J Transl Med. 2008 May 1;6:22. doi: 10.1186/1479-5876-6-22.
Zotero 插件